NanoViricides (NNVC) Competitors

$1.64 +0.09 (+5.81%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.63 -0.01 (-0.43%)

As of 05/22/2026 07:56 PM Eastern

NNVC vs. PYXS, GNLX, ACOG, OKUR, and THAR

Should you buy NanoViricides stock or one of its competitors? MarketBeat compares NanoViricides with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NanoViricides include Pyxis Oncology (PYXS), Genelux (GNLX), Alpha Cognition (ACOG), OnKure Therapeutics (OKUR), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry.

How does NanoViricides compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Pyxis Oncology has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

NanoViricides has lower revenue, but higher earnings than Pyxis Oncology. NanoViricides is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	8.96	-$79.62M	-$1.31	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

NanoViricides' return on equity of -87.90% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
NanoViricides	N/A	-87.90%	-78.69%

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pyxis Oncology currently has a consensus price target of $6.83, indicating a potential upside of 248.64%. Given Pyxis Oncology's higher possible upside, research analysts plainly believe Pyxis Oncology is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Pyxis Oncology had 9 more articles in the media than NanoViricides. MarketBeat recorded 14 mentions for Pyxis Oncology and 5 mentions for NanoViricides. Pyxis Oncology's average media sentiment score of 0.49 beat NanoViricides' score of 0.12 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NanoViricides	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pyxis Oncology beats NanoViricides on 8 of the 14 factors compared between the two stocks.

How does NanoViricides compare to Genelux?

Genelux (NASDAQ:GNLX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, NanoViricides had 5 more articles in the media than Genelux. MarketBeat recorded 5 mentions for NanoViricides and 0 mentions for Genelux. NanoViricides' average media sentiment score of 0.12 beat Genelux's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
NanoViricides	Neutral

Genelux has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

NanoViricides has lower revenue, but higher earnings than Genelux. NanoViricides is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

NanoViricides' return on equity of -87.90% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
NanoViricides	N/A	-87.90%	-78.69%

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 516.44%. Given Genelux's higher possible upside, equities analysts plainly believe Genelux is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

37.3% of Genelux shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

NanoViricides beats Genelux on 9 of the 14 factors compared between the two stocks.

How does NanoViricides compare to Alpha Cognition?

NanoViricides (NYSE:NNVC) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

10.3% of NanoViricides shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 14.0% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NanoViricides has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

NanoViricides has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Alpha Cognition	-232.23%	-58.35%	-45.99%

In the previous week, Alpha Cognition had 1 more articles in the media than NanoViricides. MarketBeat recorded 6 mentions for Alpha Cognition and 5 mentions for NanoViricides. Alpha Cognition's average media sentiment score of 0.56 beat NanoViricides' score of 0.12 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has a consensus price target of $16.00, suggesting a potential upside of 173.50%. Given Alpha Cognition's higher possible upside, analysts clearly believe Alpha Cognition is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

NanoViricides has higher earnings, but lower revenue than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Alpha Cognition	$10.22M	12.46	-$20.67M	-$1.35	N/A

Summary

Alpha Cognition beats NanoViricides on 9 of the 14 factors compared between the two stocks.

How does NanoViricides compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

OnKure Therapeutics' return on equity of -61.02% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
NanoViricides	N/A	-87.90%	-78.69%

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

OnKure Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

OnKure Therapeutics presently has a consensus target price of $27.00, indicating a potential upside of 541.33%. Given OnKure Therapeutics' higher probable upside, equities research analysts clearly believe OnKure Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NanoViricides is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

In the previous week, NanoViricides had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for NanoViricides and 1 mentions for OnKure Therapeutics. NanoViricides' average media sentiment score of 0.12 beat OnKure Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NanoViricides	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NanoViricides beats OnKure Therapeutics on 7 of the 12 factors compared between the two stocks.

How does NanoViricides compare to Tharimmune?

NanoViricides (NYSE:NNVC) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

In the previous week, NanoViricides had 4 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for NanoViricides and 1 mentions for Tharimmune. NanoViricides' average media sentiment score of 0.12 beat Tharimmune's score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tharimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NanoViricides' return on equity of -87.90% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Tharimmune	N/A	-588.45%	-264.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NanoViricides is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

NanoViricides has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Summary

NanoViricides beats Tharimmune on 10 of the 12 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$35.50M	$797.03M	$6.41B	$23.07B
Dividend Yield	N/A	4.84%	2.76%	4.09%
P/E Ratio	-2.28	1.46	21.01	30.66
Price / Sales	N/A	124.41	555.71	24.56
Price / Cash	N/A	20.07	44.57	25.15
Price / Book	2.48	7.59	10.37	4.73
Net Income	-$8.29M	-$3.91M	$3.56B	$1.07B
7 Day Performance	10.81%	0.50%	5.10%	1.95%
1 Month Performance	26.15%	80.42%	3.58%	0.85%
1 Year Performance	-8.38%	123.37%	34.18%	28.44%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNVC NanoViricides	0.4638 of 5 stars	$1.64 +5.8%	N/A	+10.8%	$35.50M	N/A	N/A	20	High Trading Volume
PYXS Pyxis Oncology	3.5691 of 5 stars	$1.91 -5.4%	$6.83 +257.8%	+63.3%	$127.98M	$13.86M	N/A	60	Analyst Downgrade Analyst Revision
GNLX Genelux	1.6726 of 5 stars	$2.80 -1.8%	$18.00 +542.9%	+17.3%	$127.79M	$10K	N/A	10
ACOG Alpha Cognition	4.3948 of 5 stars	$5.80 +0.9%	$16.00 +175.9%	-32.7%	$125.20M	$10.22M	N/A	N/A	Analyst Forecast
OKUR OnKure Therapeutics	2.7796 of 5 stars	$3.30 +7.1%	$27.00 +718.2%	+95.8%	$124.42M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 5/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. PYXS, GNLX, ACOG, OKUR, and THAR

How does NanoViricides compare to Pyxis Oncology?

Summary

How does NanoViricides compare to Genelux?

Summary

How does NanoViricides compare to Alpha Cognition?

Summary

How does NanoViricides compare to OnKure Therapeutics?

Summary

How does NanoViricides compare to Tharimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. PYXS, GNLX, ACOG, OKUR, and THAR

How does NanoViricides compare to Pyxis Oncology?

Which has more volatility and risk, PYXS or NNVC?

Which has stronger valuation and earnings, PYXS or NNVC?

Is PYXS or NNVC more profitable?

Do institutionals and insiders believe in PYXS or NNVC?

Do analysts rate PYXS or NNVC?

Does the media refer more to PYXS or NNVC?

Summary

How does NanoViricides compare to Genelux?

Does the media prefer GNLX or NNVC?

Which has more volatility & risk, GNLX or NNVC?

Which has higher earnings and valuation, GNLX or NNVC?

Is GNLX or NNVC more profitable?

Do analysts rate GNLX or NNVC?

Do institutionals & insiders hold more shares of GNLX or NNVC?

Summary

How does NanoViricides compare to Alpha Cognition?

Do insiders & institutionals hold more shares of NNVC or ACOG?

Which has more risk and volatility, NNVC or ACOG?

Is NNVC or ACOG more profitable?

Does the media prefer NNVC or ACOG?

Do analysts rate NNVC or ACOG?

Which has preferable earnings & valuation, NNVC or ACOG?

Summary

How does NanoViricides compare to OnKure Therapeutics?

Is OKUR or NNVC more profitable?

Do institutionals and insiders believe in OKUR or NNVC?

Which has more risk & volatility, OKUR or NNVC?

Do analysts prefer OKUR or NNVC?

Which has better earnings and valuation, OKUR or NNVC?

Does the media prefer OKUR or NNVC?

Summary

How does NanoViricides compare to Tharimmune?

Does the media favor NNVC or THAR?

Do institutionals and insiders have more ownership in NNVC or THAR?

Is NNVC or THAR more profitable?

Do analysts rate NNVC or THAR?

Which has stronger earnings and valuation, NNVC or THAR?

Which has more volatility and risk, NNVC or THAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools